Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the effect of Visudyne® combination therapy (Visudyne®
[verteporfin for injection] and Lucentis™) on visual acuity outcomes. Study results will be
submitted for publication to provide data that may help physicians refine the clinical
management of patients with CNV secondary to age-related macular degeneration (AMD).